Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 27, 2013Journal of Clinical OncologyOpen Access

Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia

View Full Paper
Ask AI
Bookmark
Share

Authors

SQShukui QinShanxi Agricultural UniversityYBYuxian BaiHarbin Medical UniversityHLHo Yeong LimSamsung Medical Center

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Qin et al. (2013) studied this question.

synapsesocial.com/papers/6a11ce18a50709dd2cdcd5a6https://doi.org/10.1200/jco.2012.44.5643
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial1988 · 361 citations
  2. 2Hepatocellular Carcinoma: The Need for Progress2005 · 408 citations
  3. 3A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular Carcinoma2005 · 591 citations
  4. 4High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial2002 · 210 citations
  5. 5Global cancer statistics2011 · 55,020 citations